Cardiol Therapeutics Inc CRDL.TO is expected to show no change in quarterly revenue when it reports results on March 31 (estimated) for the period ending December 31 2024
LSEG's mean analyst estimate for Cardiol Therapeutics Inc is for a loss of 12 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Cardiol Therapeutics Inc is $9.00, above its last closing price of $0.99.
Previous quarterly performance (using preferred earnings measure in Canadian dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2024 | -0.11 | -0.11 | -0.18 | Missed | -58.8 |
Jun. 30 2024 | -0.13 | -0.13 | -0.10 | Beat | 21.1 |
Mar. 31 2024 | -0.08 | -0.10 | -0.14 | Missed | -33.3 |
Dec. 31 2023 | -0.12 | -0.12 | Met | 0 | |
Sep. 30 2023 | -0.12 | -0.12 | -0.09 | Beat | 25 |
Jun. 30 2023 | -0.12 | -0.12 | -0.12 | Met | 4 |
Mar. 31 2023 | -0.15 | -0.15 | -0.11 | Beat | 26.7 |
Dec. 31 2022 | -0.15 | -0.12 | Beat | 22.6 |
This summary was machine generated March 28 at 20:31 GMT. All figures in Canadian dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)